Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keisuke Aiba

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
ESMO Open|March 14, 2018
Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive <i>EGFR</i> mutationsSatoshi Oizumi, Shunichi Sugawara, Koichi Minato, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 22, 2009
Gemtuzumab ozogamicin (GO) in relapsed/refractory patients with acute myeloid leukemiaYuko Yamaguchi, Noriko Usui, Nobuaki Dobashi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 2, 2003
[Globalization of clinical trials]Hideyuki Akaza, Masahiro Fukuoka, Atsushi Ohtsu, et al.
Clinical Colorectal Cancer|December 19, 2017
Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon CancerTetsuya Kusumoto, Eiji Sunami, Mitsuyoshi Ota, et al.
Clinical Colorectal Cancer|January 10, 2020
S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority TrialEiji Sunami, Tetsuya Kusumoto, Mitsuyoshi Ota, et al.
Cancer Medicine|October 14, 2016
Clinical significance of granule-containing myeloma cells in patients with newly diagnosed multiple myelomaKazuhito Suzuki, Shingo Yano, Kaichi Nishiwaki, et al.
International Journal of Clinical Oncology|June 18, 2015
Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summaryHideki Takeuchi, Toshiaki Saeki, Keisuke Aiba, et al.
International Journal of Clinical Oncology|November 8, 2020
Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015  Japan Society of Clinical Oncology Clinical Practice Guidelines for AntiemesisKenjiro Aogi, Hideki Takeuchi, Toshiaki Saeki, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 28, 2015
[The survey for anti-emetic guideline by using questioner]Toshiaki Saeki, Kazuo Tamura, Keisuke Aiba, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
ESMO Open|March 14, 2018
Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive <i>EGFR</i> mutationsSatoshi Oizumi, Shunichi Sugawara, Koichi Minato, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 22, 2009
Gemtuzumab ozogamicin (GO) in relapsed/refractory patients with acute myeloid leukemiaYuko Yamaguchi, Noriko Usui, Nobuaki Dobashi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 2, 2003
[Globalization of clinical trials]Hideyuki Akaza, Masahiro Fukuoka, Atsushi Ohtsu, et al.
Clinical Colorectal Cancer|December 19, 2017
Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon CancerTetsuya Kusumoto, Eiji Sunami, Mitsuyoshi Ota, et al.
Clinical Colorectal Cancer|January 10, 2020
S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority TrialEiji Sunami, Tetsuya Kusumoto, Mitsuyoshi Ota, et al.
Cancer Medicine|October 14, 2016
Clinical significance of granule-containing myeloma cells in patients with newly diagnosed multiple myelomaKazuhito Suzuki, Shingo Yano, Kaichi Nishiwaki, et al.
International Journal of Clinical Oncology|June 18, 2015
Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summaryHideki Takeuchi, Toshiaki Saeki, Keisuke Aiba, et al.
International Journal of Clinical Oncology|November 8, 2020
Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015  Japan Society of Clinical Oncology Clinical Practice Guidelines for AntiemesisKenjiro Aogi, Hideki Takeuchi, Toshiaki Saeki, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 28, 2015
[The survey for anti-emetic guideline by using questioner]Toshiaki Saeki, Kazuo Tamura, Keisuke Aiba, et al.
Pageof 8